vs
Mama's Creations, Inc.（MAMA）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是Mama's Creations, Inc.的1.4倍（$65.1M vs $47.3M），MESA LABORATORIES INC净利率更高（5.6% vs 1.1%，领先4.4%），Mama's Creations, Inc.同比增速更快（50.0% vs 3.6%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $3.7M），过去两年Mama's Creations, Inc.的营收复合增速更高（33.0% vs 5.1%）
Mama's Creations是一家美国食品制造企业，主要生产冷藏即食、加热即食类食品，涵盖意式肉丸、香肠、意面餐食等预制菜品，产品主要供应美国本土的零售商超、大众零售商及餐饮服务合作伙伴，主打便捷高品质的家常风味食品。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
MAMA vs MLAB — 直观对比
营收规模更大
MLAB
是对方的1.4倍
$47.3M
营收增速更快
MAMA
高出46.3%
3.6%
净利率更高
MLAB
高出4.4%
1.1%
自由现金流更多
MLAB
多$14.3M
$3.7M
两年增速更快
MAMA
近两年复合增速
5.1%
损益表 — Q3 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $47.3M | $65.1M |
| 净利润 | $540.0K | $3.6M |
| 毛利率 | 23.6% | 64.2% |
| 营业利润率 | 1.7% | 12.2% |
| 净利率 | 1.1% | 5.6% |
| 营收同比 | 50.0% | 3.6% |
| 净利润同比 | 31.7% | 316.6% |
| 每股收益（稀释后） | $0.01 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MAMAMLAB
| Q4 25 | $47.3M | $65.1M | ||
| Q3 25 | $35.2M | $60.7M | ||
| Q2 25 | $35.3M | $59.5M | ||
| Q1 25 | $33.6M | $62.1M | ||
| Q4 24 | $31.5M | $62.8M | ||
| Q3 24 | $28.4M | $57.8M | ||
| Q2 24 | $29.8M | $58.2M | ||
| Q1 24 | $26.7M | $58.9M |
净利润MAMAMLAB
| Q4 25 | $540.0K | $3.6M | ||
| Q3 25 | $1.3M | $2.5M | ||
| Q2 25 | $1.2M | $4.7M | ||
| Q1 25 | $1.6M | $-7.1M | ||
| Q4 24 | $410.0K | $-1.7M | ||
| Q3 24 | $1.1M | $3.4M | ||
| Q2 24 | $553.0K | $3.4M | ||
| Q1 24 | $1.4M | $-254.6M |
毛利率MAMAMLAB
| Q4 25 | 23.6% | 64.2% | ||
| Q3 25 | 24.9% | 61.5% | ||
| Q2 25 | 26.1% | 62.0% | ||
| Q1 25 | 27.0% | 61.8% | ||
| Q4 24 | 22.6% | 63.3% | ||
| Q3 24 | 24.2% | 61.3% | ||
| Q2 24 | 25.0% | 64.0% | ||
| Q1 24 | 29.3% | 62.1% |
营业利润率MAMAMLAB
| Q4 25 | 1.7% | 12.2% | ||
| Q3 25 | 4.8% | 7.8% | ||
| Q2 25 | 4.5% | 5.1% | ||
| Q1 25 | 5.7% | 2.4% | ||
| Q4 24 | 1.8% | 9.2% | ||
| Q3 24 | 5.7% | 6.1% | ||
| Q2 24 | 2.6% | 9.6% | ||
| Q1 24 | 7.4% | -460.6% |
净利率MAMAMLAB
| Q4 25 | 1.1% | 5.6% | ||
| Q3 25 | 3.6% | 4.1% | ||
| Q2 25 | 3.5% | 8.0% | ||
| Q1 25 | 4.8% | -11.4% | ||
| Q4 24 | 1.3% | -2.7% | ||
| Q3 24 | 4.0% | 5.9% | ||
| Q2 24 | 1.9% | 5.8% | ||
| Q1 24 | 5.3% | -432.2% |
每股收益（稀释后）MAMAMLAB
| Q4 25 | $0.01 | $0.65 | ||
| Q3 25 | $0.03 | $0.45 | ||
| Q2 25 | $0.03 | $0.85 | ||
| Q1 25 | $0.04 | $-1.30 | ||
| Q4 24 | $0.01 | $-0.31 | ||
| Q3 24 | $0.03 | $0.63 | ||
| Q2 24 | $0.01 | $0.62 | ||
| Q1 24 | $0.03 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $18.1M | $29.0M |
| 总债务越低越好 | — | $68.4M |
| 股东权益账面价值 | $49.6M | $186.7M |
| 总资产 | $84.0M | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资MAMAMLAB
| Q4 25 | $18.1M | $29.0M | ||
| Q3 25 | $9.4M | $20.4M | ||
| Q2 25 | $12.0M | $21.3M | ||
| Q1 25 | $7.2M | $27.3M | ||
| Q4 24 | $9.3M | $27.3M | ||
| Q3 24 | $7.4M | $24.3M | ||
| Q2 24 | $13.0M | $28.5M | ||
| Q1 24 | $11.0M | $28.2M |
总债务MAMAMLAB
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
股东权益MAMAMLAB
| Q4 25 | $49.6M | $186.7M | ||
| Q3 25 | $29.6M | $178.5M | ||
| Q2 25 | $26.4M | $172.5M | ||
| Q1 25 | $24.9M | $159.8M | ||
| Q4 24 | $23.0M | $155.2M | ||
| Q3 24 | $22.3M | $161.5M | ||
| Q2 24 | $20.3M | $150.7M | ||
| Q1 24 | $19.6M | $145.4M |
总资产MAMAMLAB
| Q4 25 | $84.0M | $434.8M | ||
| Q3 25 | $51.2M | $430.4M | ||
| Q2 25 | $52.7M | $435.7M | ||
| Q1 25 | $47.1M | $433.3M | ||
| Q4 24 | $47.9M | $433.3M | ||
| Q3 24 | $43.0M | $454.1M | ||
| Q2 24 | $47.2M | $440.4M | ||
| Q1 24 | $45.1M | $446.8M |
负债/权益比MAMAMLAB
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.9M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $3.7M | $18.0M |
| 自由现金流率自由现金流/营收 | 7.8% | 27.7% |
| 资本支出强度资本支出/营收 | 0.4% | 1.1% |
| 现金转化率经营现金流/净利润 | 7.16× | 5.17× |
| 过去12个月自由现金流最近4个季度 | $6.0M | $37.9M |
8季度趋势，按日历期对齐
经营现金流MAMAMLAB
| Q4 25 | $3.9M | $18.8M | ||
| Q3 25 | $-1.7M | $8.2M | ||
| Q2 25 | $6.0M | $1.9M | ||
| Q1 25 | $-857.0K | $12.7M | ||
| Q4 24 | $4.8M | $18.1M | ||
| Q3 24 | $-2.4M | $5.3M | ||
| Q2 24 | $3.6M | $10.7M | ||
| Q1 24 | $6.7M | $12.9M |
自由现金流MAMAMLAB
| Q4 25 | $3.7M | $18.0M | ||
| Q3 25 | $-2.2M | $7.1M | ||
| Q2 25 | $5.5M | $884.0K | ||
| Q1 25 | $-930.0K | $11.9M | ||
| Q4 24 | $2.5M | $17.3M | ||
| Q3 24 | $-4.0M | $3.5M | ||
| Q2 24 | $2.5M | $9.9M | ||
| Q1 24 | $6.6M | $12.3M |
自由现金流率MAMAMLAB
| Q4 25 | 7.8% | 27.7% | ||
| Q3 25 | -6.2% | 11.7% | ||
| Q2 25 | 15.5% | 1.5% | ||
| Q1 25 | -2.8% | 19.2% | ||
| Q4 24 | 8.0% | 27.6% | ||
| Q3 24 | -14.1% | 6.0% | ||
| Q2 24 | 8.4% | 16.9% | ||
| Q1 24 | 24.8% | 21.0% |
资本支出强度MAMAMLAB
| Q4 25 | 0.4% | 1.1% | ||
| Q3 25 | 1.5% | 1.8% | ||
| Q2 25 | 1.5% | 1.7% | ||
| Q1 25 | 0.2% | 1.2% | ||
| Q4 24 | 7.2% | 1.3% | ||
| Q3 24 | 5.6% | 3.1% | ||
| Q2 24 | 3.8% | 1.5% | ||
| Q1 24 | 0.4% | 0.9% |
现金转化率MAMAMLAB
| Q4 25 | 7.16× | 5.17× | ||
| Q3 25 | -1.31× | 3.32× | ||
| Q2 25 | 4.85× | 0.40× | ||
| Q1 25 | -0.54× | — | ||
| Q4 24 | 11.71× | — | ||
| Q3 24 | -2.10× | 1.54× | ||
| Q2 24 | 6.58× | 3.17× | ||
| Q1 24 | 4.79× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MAMA
暂无分部数据
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
